lansoprazole has been researched along with Connective Tissue Diseases in 2 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 7.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 3.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors." | 1.31 | Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isoda, K | 1 |
| Takeuchi, T | 1 |
| Kotani, T | 1 |
| Hirano-Kuwata, S | 1 |
| Shoda, T | 1 |
| Hata, K | 1 |
| Yoshida, S | 1 |
| Makino, S | 1 |
| Hanafusa, T | 1 |
| Prasad, R | 1 |
| De Silva, M | 1 |
2 other studies available for lansoprazole and Connective Tissue Diseases
| Article | Year |
|---|---|
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Topics: Calcineurin Inhibitors; Connective Tissue Diseases; Cyclosporine; Cytochrome P-450 CYP2C19; Drug Int | 2014 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant | 2002 |